Our long-term corporate strategy is to build our portfolio based upon our original research and biotechnology development to give patients access to the medicines they need.
We focus our resources on areas where we have specialised knowledge: Original research into CNS disorders, women's healthcare, and biosimilar product development.
Our strategy provides clear direction for each element of the portfolio. We have identified a number of key strategic pillars to support our 2018-2028 objectives. These pillars include a long-term goal to build the portfolio based upon our original research and biotechnology development. Finally, the pillars of our traditional and branded generic portfolio remain important cornerstones for our current business.
All pillars contribute to the successful implementation of our strategy and our mission to provide high-quality medicines worldwide.